Hepatocellular carcinoma demonstrates sorafenib resistance through PLAG1-GPX4 interactions, which inhibits sorafenib-triggered ferroptosis via the PVT1/miR-195-5p pathway[63], with additional contributions from the NeuroD1-GPX4 pathway[64]. The gene discussed is GPX4; the disease is hepatocellular carcinoma.